Lumida
/PGEN
⌘K
Precigen Inc

Precigen Inc

PGEN
$6.85USD+2.54%+0.17 today

MARKET CAP

2.5B

P/E (TTM)

FWD P/E

DAY RANGE

$7 – $7

52W RANGE

$3
$8

AI Summary

Stalk
StalkMedium

PGEN remains in a Stage 2 advancing structure above the 50-day SMA, but the active Bullish Exhaustion pattern at late-August highs signals waning upside momentum. Price is pulling back into declining 9- and 20-day EMAs with RSI in a neutral range, offering a buy-on-dip setup. Medium-term bias stays bullish, while short-term timing is neutral—entries are best deferred until clear acceptance off the EMA zone.

  • Q2 revenue $55M; Papimius sales $53.1M, up 145% QoQ
  • FDA approval and 7-year orphan drug exclusivity for RRP therapy
  • Insiders sold ~235K shares (~$1.38M), flagging possible concern
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$14.3M$26.9M$6.2M$3.9M$9.7M
YoY %-55.4%+88.6%-76.9%-36.9%+146.7%
P / Sales51.4x11.0x55.4x76.4x135.1x
EV / Sales66.6x14.2x59.4x88.9x145.9x
Gross Profit, Adj.$8.5M$20.6M$106,000$-342,000$4.9M
YoY %-68.0%+141.4%-99.5%-422.6%+1521.3%
Margin %59.7%76.4%1.7%-8.7%50.2%
EV / Gross Profit111.4x18.5x3488.3x-1020.1x290.6x
EBITDA, Adj.$-77.6M$-63.8M$-82.3M$-90.2M$-103.4M
YoY %-14.2%+17.8%-28.8%-9.6%-14.7%
Margin %-544.2%-237.2%-1321.4%-2297.6%-1067.8%
EV / EBITDA-12.2x-6.0x-4.5x-3.9x-13.7x
EBIT$-91.9M$-75.7M$-99.8M$-135.0M$-110.5M
YoY %-6.5%+17.6%-31.7%-35.4%+18.2%
Margin %-644.5%-281.4%-1602.5%-3440.2%-1141.1%
EV / EBIT-10.3x-5.0x-3.7x-2.6x-12.8x
Net Income$-92.2M$28.3M$-95.9M$-126.2M$-429.6M
YoY %+46.0%+130.7%-438.7%-31.6%-240.4%
Net Margin-646.0%105.2%-1540.6%-3216.2%-4436.6%
EPS (GAAP)-$0.47$0.14-$0.39-$0.47-$1.37
YoY %+53.9%+129.8%-378.6%-20.5%-191.5%